“Change creates angst: it creates pressures, it creates employee dissatisfaction, it creates environments that most medical practices aren’t used to participating in,” said Erich Mounce, MSHS, Chief Executive Officer, West Cancer Center, Memphis, TN, in his introduction to an intriguing [ Read More ]
With the advent of a shift to value-based care and increasing accountability for effective care, patient engagement is emerging as the primary mechanism to effect change. However, the sheer volume of patients means that physicians and nurses cannot hope to [ Read More ]
A panel discussion at the 2017 Cancer Center Business Summit revealed continuing gaps in the evolution of healthcare reform among providers, payers, and patients with cancer. Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY—an [ Read More ]
April Christensen points out the value of clinical trials for patients as well as medical practices.
April Christensen points out the significance of finding the right practice manager organization and the resources they have to offer.
April Christensen speaks to how practice managers need to adjust to the ever-changing oncology market.
Randomized Phase 3, Multicenter, Open-Label Study Comparing Evofosfamide (EVO) in Combination with Doxorubicin (D) versus D Alone in Patients with Advanced Soft-Tissue Sarcoma (STS): Study TH-CR-406/SARC021
This randomized phase 3 study compared the efficacy and safety of evofosfamide (EVO) plus doxorubicin (D) with D alone in patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy for advanced disease. Patients on EVO+D could receive [ Read More ]
Real-Life Clinical Outcomes of Pazopanib Treatment in Patients with STS: A Japanese Musculoskeletal Oncology Group Study
The efficacy and safety of pazopanib were assessed in 156 Japanese patients with relapsed soft-tissue sarcoma (STS). This was a retrospective study based on postmarketing surveillance data. To be included in this study, patients’ primary tumor had to arise from [ Read More ]
This open-label phase 2 trial assessed the activity, safety, and tolerability of axitinib 5 mg orally twice daily in patients with advanced soft-tissue sarcoma (STS) who were unsuitable for or relapsed after standard chemotherapy. This report focuses on patients with [ Read More ]